Roland Eid

Roland Eid

Auto-generated profile, based on publicly available information

Roland Eid

Department of Hematology & Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
Joe MehannaJoe Mehanna
Joe Mehanna
FHFadi Haddad
Fadi Haddad
RERoland Eid
Roland Eid
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
HKHampig Raphael Kourie
Hampig Raphael Kourie
Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy.

1 May 2020 in Future Oncology
Verified
Journal Article
Open access
RERonaldo Elkaddoum
Ronaldo Elkaddoum
FHFadi Haddad
Fadi Haddad
RERoland Eid
Roland Eid
HKHampig Raphael Kourie
Hampig Raphael Kourie

17 October 2019 in Immunotherapy
Verified
Journal Article
Closed access
EMElissar Moujaess
Elissar Moujaess
FHFadi Haddad
Fadi Haddad
RERoland Eid
Roland Eid
HKHampig Raphael Kourie
Hampig Raphael Kourie
The use of immune checkpoint inhibitors has been approved in the advanced and metastatic setting for many types of solid tumors. Nonetheless, their role in the adjuvant setting is limited to the treatment of surgically resected melanoma. Ipilimumab was the first immune checkpoint inhibitor approved for this indication, followed by nivolumab and pembrolizumab. Many ongoing trials are evaluating these molecules in the postoperative setting, alone or in combination with other therapies. Preliminary results are promising regarding the treatment of other cutaneous tumors, lung cancers, head and neck squamous cell carcinomas, bladder cancer and renal cell carcinomas. Some data assessing their use for the adjuvant treatment of esophageal, colorectal, ovarian cancer and other solid tumors are similarly emerging.

6 December 2021 in Immunotherapy
Verified
Journal Article
Closed access
JZJoseph Zouein
Joseph Zouein
FHFadi Haddad
Fadi Haddad
RERoland Eid
Roland Eid
HKHampig Raphael Kourie
Hampig Raphael Kourie
Lung cancer is the second most common cancer worldwide and the leading cause of death among cancers. The progressive approvals of immunotherapy as first-line treatment options have helped improve c...

22 January 2020 in Pharmacogenomics
Verified
Journal Article
Closed access
GHGaëlle Haddad
Gaëlle Haddad
MSMarie Christelle Saadé
Marie Christelle Saadé
RERoland Eid
Roland Eid
FHFadi Haddad
Fadi Haddad
HKHampig Raphael Kourie
Hampig Raphael Kourie
The evolution of precision medicine in the field of oncology has led to a radical change in the course of malignancies. PARP inhibitors are drugs that block the activity of the PARP enzyme responsi...

14 January 2021 in Biomarkers in Medicine
Verified
Journal Article
Closed access
LBLynn Bitar
Lynn Bitar
JZJoseph Zouein
Joseph Zouein
FHFadi Haddad
Fadi Haddad
RERoland Eid
Roland Eid
HKHampig R Kourie
Hampig R Kourie
Metastatic colorectal cancer is the second most common cause of cancer death. Standard chemotherapy in combination with targeted therapies represent the backbone for the treatment of advanced disea...